We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add DexCom (DXCM) to Your Portfolio Now
Read MoreHide Full Article
DexCom (DXCM - Free Report) is progressing well on prudent acquisitions along with product portfolio expansion. Impressive contributions from its core segments and solid international expansion have also been key growth drivers.
This $24.09-billion leader in the field of design, development and commercialization of continuous glucose monitoring systems has an expected earnings growth rate of 36.7% for the next five years. Also, this Zacks Rank #2 (Buy) company has a trailing four-quarter positive earnings surprise of 128.3%, on average.
The stock has a Growth Score of A. Our research shows that stocks with a GrowthScore of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, are better picks than most. In the past six months, the stock has rallied 86.7% against the 10.2% decline of its industry. The stock also surged 141.4% against the S&P 500 index’s 11.8% decline.
Let’s delve deeper into the factors working in favor of the company.
Strong Product Portfolio: DexCom's FDA-cleared CGM system, the DexCom G4 Platinum, has been significantly boosting the top line. In January 2020, Tandem Diabetes launched its latest integrated pump offering viz. the Control-IQ system which integrates the DexCom G6 sensor and its type zero algorithm to automated insulin delivery.
DexCom’s Insulet and Lilly diabetes management products continue to progress well. In December 2019, Insulet commenced the important trial, and thereby has been on track for a launch later in 2020. The company’s commercial agreement with Eli Lilly was officially signed last December and signifies another step toward bringing their system to the market with G6, which will initially focus on a smart pen offering.
Additionally, the company is well poised to achieve long-term target on the back of expansion of the G6 rollout and improved access to Continuos Glucose Monitoring (CGM)
Strategic Collaborations & Acquisitions: DexCom has been gaining from recent collaborative agreements. During the fourth quarter of 2019, DexCom’s collaborative work with UnitedHealthcare has displayed notable progress with the company being optimistic about CGM in its Type 2 population in 2020. The company looks forward to expanding the presence of CGM for type 2 customers through additional partnerships with programs offered by digital health players like Onduo, Livongo and WellDoc.
Solid Guidance: For 2020, DexCom anticipates revenues between $1.73 billion and $1.78 billion, indicating an improvement of 17-20% year over year. Per management, similar to the factors in 2019, this projected revenue growth is backed by expectations of increased volume growth owing to growing awareness and access of DexCom CGM.
Estimates Trend
The company is witnessing a positive estimate revision trend for 2020. Over the past 60 days, the Zacks Consensus Estimate for its earnings has risen 24.6% to $2.23 per share.
The Zacks Consensus Estimate for the company’s first-quarter 2020 revenues is pegged at $357.5 million, suggesting a 27.5% rise from the year-ago reported number.
Key Picks
Some othertop-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , AmerisourceBergen and Integra LifeSciences Inc (IART - Free Report) .
AmerisourceBergen’s long-term earnings growth rate is estimated at 7.4%. The company presently carries a Zacks Rank #2.
Integra’s long-term earnings growth rate is estimated at 11.9%. It currently carries a Zacks Rank #2.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Here's Why You Should Add DexCom (DXCM) to Your Portfolio Now
DexCom (DXCM - Free Report) is progressing well on prudent acquisitions along with product portfolio expansion. Impressive contributions from its core segments and solid international expansion have also been key growth drivers.
This $24.09-billion leader in the field of design, development and commercialization of continuous glucose monitoring systems has an expected earnings growth rate of 36.7% for the next five years. Also, this Zacks Rank #2 (Buy) company has a trailing four-quarter positive earnings surprise of 128.3%, on average.
The stock has a Growth Score of A. Our research shows that stocks with a GrowthScore of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, are better picks than most. In the past six months, the stock has rallied 86.7% against the 10.2% decline of its industry. The stock also surged 141.4% against the S&P 500 index’s 11.8% decline.
Let’s delve deeper into the factors working in favor of the company.
Strong Product Portfolio: DexCom's FDA-cleared CGM system, the DexCom G4 Platinum, has been significantly boosting the top line. In January 2020, Tandem Diabetes launched its latest integrated pump offering viz. the Control-IQ system which integrates the DexCom G6 sensor and its type zero algorithm to automated insulin delivery.
DexCom’s Insulet and Lilly diabetes management products continue to progress well. In December 2019, Insulet commenced the important trial, and thereby has been on track for a launch later in 2020. The company’s commercial agreement with Eli Lilly was officially signed last December and signifies another step toward bringing their system to the market with G6, which will initially focus on a smart pen offering.
Additionally, the company is well poised to achieve long-term target on the back of expansion of the G6 rollout and improved access to Continuos Glucose Monitoring (CGM)
Strategic Collaborations & Acquisitions: DexCom has been gaining from recent collaborative agreements. During the fourth quarter of 2019, DexCom’s collaborative work with UnitedHealthcare has displayed notable progress with the company being optimistic about CGM in its Type 2 population in 2020. The company looks forward to expanding the presence of CGM for type 2 customers through additional partnerships with programs offered by digital health players like Onduo, Livongo and WellDoc.
Solid Guidance: For 2020, DexCom anticipates revenues between $1.73 billion and $1.78 billion, indicating an improvement of 17-20% year over year. Per management, similar to the factors in 2019, this projected revenue growth is backed by expectations of increased volume growth owing to growing awareness and access of DexCom CGM.
Estimates Trend
The company is witnessing a positive estimate revision trend for 2020. Over the past 60 days, the Zacks Consensus Estimate for its earnings has risen 24.6% to $2.23 per share.
The Zacks Consensus Estimate for the company’s first-quarter 2020 revenues is pegged at $357.5 million, suggesting a 27.5% rise from the year-ago reported number.
Key Picks
Some othertop-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , AmerisourceBergen and Integra LifeSciences Inc (IART - Free Report) .
ResMed has a projected long-term earnings growth rate of 12%. It currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
AmerisourceBergen’s long-term earnings growth rate is estimated at 7.4%. The company presently carries a Zacks Rank #2.
Integra’s long-term earnings growth rate is estimated at 11.9%. It currently carries a Zacks Rank #2.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>